Rapamycin + AMPK-axis drugs (acarbose / metformin): additive via distinct pathways, and untested as a combination in humans

Evidence desert · confidence 70% · Atlas ID H9

The gap

In mice, combining rapamycin with a diabetes drug called acarbose extended life more than either drug alone - but only in males; in females it was no better than rapamycin by itself. A different diabetes drug, metformin, works through much of the same machinery as rapamycin (via a shared checkpoint called AMPK), so combining them might not add much. But be careful with that reasoning: two drugs hitting different targets do not automatically add up - they can still overlap further downstream, or interact in unexpected ways. Nobody in this Atlas's collection has run a human trial combining any of these.

Technical framing: Animal combination data are suggestive but the human evidence for combining mTOR inhibition with AMPK-axis geroprotectors is a desert. QUANTIFIED (ITP; SOURCING GAP flagged 2026-08-30 - the ITP combination publication is not yet entered in this corpus under a study code, so this figure is currently uncheckable from the supporting list): rapamycin + acarbose from 9 months extended MALE lifespan MORE than either drug alone, while in FEMALES the combination was no better than rapamycin alone. HAR2014 established acarbose's male-skewed lifespan effect. The AMPK arm converges back onto mTOR mechanistically: ZHO2001 metformin acts via AMPK, GWI2008 AMPK phosphorylates raptor to gate mTORC1, HOW2017 metformin inhibits hepatic mTORC1 dose-dependently via AMPK - which raises the opposite possibility that metformin + rapamycin are partly REDUNDANT on the mTORC1 node. Human signal exists only for observational data (BAN2014: type-2 diabetics on metformin outlived non-diabetic controls - a result subject to the usual immortal-time and prescription-bias caveats of the metformin-survivorship literature, and not treated here as causal). No study IN THIS CORPUS - animal or human - cleanly separates ADDITIVE (distinct pathways) from REDUNDANT (same node) for these pairs, and this corpus holds no human combination trial. SCOPE (2026-08-30): this block previously read 'No study - animal or human -', an absence claim about the whole literature that a curated corpus cannot support. Gaps here are computed against this Atlas, not against PubMed. LOGIC NOTE: distinct proximal mechanisms do not entail additivity. Two drugs can hit different targets and still converge downstream, interact non-linearly, or show sex- and strain-dependent interaction - which is exactly what the ITP combination data themselves show.

The hypothesis

Educated guess: rapamycin plus acarbose may add up to a bigger benefit, since they work through different routes — but that does not follow automatically, and rapamycin plus metformin may add little extra lifespan because they overlap on the same mTORC1 switch. Which of the three outcomes (additive, redundant, or something in between) actually happens is unresolved; metformin may still be worth pairing for its effect on blood sugar.

Technical framing: Rapamycin combined with a glucose-route geroprotector (acarbose) may be ADDITIVE because the second drug works largely outside mTOR, whereas rapamycin combined with an AMPK-mTORC1 drug (metformin) may be largely REDUNDANT on the mTORC1 node and yield sub-additive gains. This is a prediction from mechanism, not an inference the data compel: distinct targets do not guarantee additivity, and whether each pairing is additive, redundant or synergistic is unresolved. A secondary possibility worth testing separately is that metformin's main value alongside rapamycin is not additive longevity but mitigation of rapamycin's glucose intolerance.

How it could be tested

Factorial mouse lifespan/healthspan study (vehicle / rapamycin / acarbose / metformin / rapamycin+acarbose / rapamycin+metformin), sex-stratified, with mTORC1 (S6K/4E-BP1) and AMPK (raptor-Ser792) readouts plus glucose tolerance. Test for statistical super-additivity. Prediction: rapamycin+acarbose is additive on lifespan; rapamycin+metformin is sub-additive on lifespan but restores glucose tolerance. Follow with a human factorial healthspan-biomarker trial on the additive pair.

Related studies

Year	Evidence	Study
2014	A	Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males HAR2014 Beyond rapamycin, the same ITP program found acarbose extended male median lifespan by 22% - evidence that the registry surfaces real positive hits too, not only negative results.
2001	M	Role of AMP-activated protein kinase in mechanism of metformin action ZHO2001 Metformin activates AMPK, suppressing hepatic gluconeogenesis and lipogenesis.
2008	M	AMPK phosphorylation of raptor mediates a metabolic checkpoint GWI2008 Found a SECOND way the energy sensor AMPK shuts mTORC1 down. Besides acting through TSC2, AMPK directly phosphorylates Raptor - the core mTORC1 subunit - to halt growth when energy runs low. This 'metabolic checkpoint' is exactly the switch that drugs like metformin and exercise tap into.
2017	M	Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex HOW2017 Pinned down HOW the diabetes drug metformin - a major longevity candidate - actually reaches mTOR. In the liver, metformin lowers cellular energy, and at low doses this shuts down mTORC1 specifically through AMPK and the TSC complex. Direct mechanistic bridge between a widely-used drug, energy sensing, and the mTOR pathway.
2014	H	Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls BAN2014 Diabetic patients started on metformin had longer median survival than matched non-diabetic controls without the drug. Retrospective and observational: consistent with a survival benefit, but confounding by indication and healthy-adherer effects cannot be excluded.
2015	A	Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system ARR2015 Intermittent rapamycin regimens (weekly, or every 5 days) largely spared glucose tolerance, pyruvate tolerance, fasting glucose and insulin, beta-cell function and the immune system, while still inhibiting mTORC1 -- unlike daily dosing, which impaired all of them. IMPORTANT SCOPE: this study measured side effects only. It did NOT measure lifespan or any other benefit endpoint, so it shows the harm can be reduced, not that the benefit is retained. For evidence that a non-continuous schedule preserves a survival benefit, see BIT2016.
2025	H	Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results MOE2025 First completed long-term RCT of rapamycin for healthy human aging (NCT04488601, 48 weeks, n=114). Primary endpoint (visceral fat by DXA) showed NO significant change (p=0.942) - a null result exactly as pre-registered. Secondary endpoints were more promising: women on the 10mg/week dose had significant improvements in lean muscle mass and self-reported pain. A textbook example of why the pre-registered primary endpoint, not the most exciting secondary finding, is what should drive the headline conclusion.

← All open questions